Summary
This study is open to all Gastric Cancer (GC) / Gastro-oesophageal junction cancer (GEJC) patients, as well as patients with other solid tumour types with FGFR2b ≥1% as determined by central testing.
It is investigating how safe and tolerable an antibody-drug conjugate that targets FGFR2b, called BG-C137 is, as well as how it interacts in the body and its anti-tumour activity. This will be done in two phases.
Participants should have had prior systemic therapy for their advanced or metastatic disease, with specific prior therapy requirements applying to each phase of the study.
In Phase 1a (Dose Escalation and Safety Expansion), sequential cohorts of increasing dose levels of intravenous BG-C137 will be evaluated. Participants for whom further standard treatment is not available, not tolerated or determined not appropriate based on the investigator's judgement.
In Phase 1b (Dose Expansion), the recommended dose(s) of BG-C137 as determined in Phase 1a will be evaluated in people with select cancer types. Participants who have received at least 1 or 2 prior lines of systemic therapy, which included a fluoropyrimidine and/or a platinum in the advanced or metastatic setting are eligible.